Longitude Capital
VC Fund
Menlo Park, United States
Longitude Capital is a VC fund in Menlo Park focused on Health Care and Biotechnology. Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance the quality of life, and/or reduce system costs. They invest in both privately held and publicly traded life science companies through a variety of investment approaches. Since2006, Longitude Capital has raised over $1.2 billion across three funds and demonstrated an ability to source, manage and exit attractive investments across multiple market cycles.Their venture growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile, and attractive expected returns within three to five years from the initial investment.Longitude Capital seeks to identify new investment opportunities by tapping into their broad network of industry relationships or through the execution of intensive thematic research into emerging therapeutic areas or industry sub-sectors. They utilize a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity and equity-linked instruments.
- Total investments:
- 149
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $50M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Longitude Capital invests in
Stages Longitude Capital invests in
Countries Longitude Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 12 contacts → | |||
Round size
- Series A
- $17M–$85M
- Series B
- $15M–$117M
- Series C
- $30M–$175M
Investment Focus
Industry
- Health Care 67 (45%)
- Biotechnology 59 (40%)
- Medical 31 (21%)
- Therapeutics 31 (21%)
- Pharmaceutical 27 (18%)
Stage
- Series B 31 (21%)
- Series A 28 (19%)
- Series C 24 (16%)
- Series D 12 (8%)
- Funding Round 7 (5%)
Country
- United States 80 (54%)
- Ireland 4 (3%)
- Canada 2 (1%)
- Switzerland 2 (1%)
- France 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Amar Patel
Associate
|
Associate | Total investments: 0 | Find email | |
Brian Liu
Principal; Vice President
|
Principal; Vice President | Total investments: 3 | Find email | |
David Hirsch
Managing Director
|
Managing Director | Total investments: 13 | Find email | |
Juliet Tammenoms Bakker
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 13 | Find email | |
Karthik Bolisetty
Associate
|
Associate | Total investments: 0 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $275M / Post-IPO Equity / Jul 27, 2026 | ||
| cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions. | $180M / Series A / May 20, 2026 | ||
| AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions. | $200M / Series A / Jan 09, 2026 | ||
| Ventaris Surgical is a medical equipment company that provides surgical instruments to specialists. | $30.7M / Series A / Jan 09, 2026 | ||
| Veradermics is a dermatology-focused biopharmaceutical company that develops treatments for common skin and hair conditions. Its lead drug candidate, VDPHL01, is an extended-release oral minoxidil being tested in Phase 3 clinical trials for pattern hair loss in both women and men. The company also has pipeline programs targeting conditions such ascommon warts, molluscum contagiosum, and atopic dermatitis. | $150M / Series C / Oct 16, 2025 | ||
| Cohere Health is a healthcare technology company, focused on improving the efficiency and effectiveness of healthcare delivery. Cohere Health aims to simplify the complexities of the healthcare system by leveraging technology to streamline processes, enhance communication, and ultimately improve patient outcomes. The company may provide solutionsto various stakeholders in the healthcare ecosystem, including patients, providers, and payers. | $90M / Series C / May 14, 2025 | ||
| CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases. | $100M / Post-IPO Equity / May 12, 2025 | ||
| MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases. Its therapies include paired vagus nerve stimulation system (Paired VNS System) and wireless neurostimulation system for the treatment of chronic pain, post-stroke upper limb mobility issues, and variousneurological indications that enable healthcare practitioners to treat post-stroke upper limb mobility issues.Founded in 2007, MicroTransponder is headquartered in Dallas, Texas. | $65M / Series F / Mar 12, 2025 | ||
| Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders. | $65M / Series A / Jan 28, 2025 | ||
| FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices. | Jan 07, 2025 | ||
| See all 149 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Longitude Capital invest in?
Longitude Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 149 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Longitude Capital's check size?
Longitude Capital typically joins rounds of $17M–$85M at Series A, $15M–$117M at Series B and $30M–$175M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Longitude Capital participates in.
How do I contact Longitude Capital?
Public channels for Longitude Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Longitude Capital?
The team at Longitude Capital includes Amar Patel (Associate), Brian Liu (Principal; Vice President) and David Hirsch (Managing Director), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
